Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa

American Journal of Respiratory and Critical Care Medicine

Volumn 184, Issue 1, 2011, Pages 106-115

  Lu, Qin ^a   Yang, Jianxin ^b   Liu, Zhihai ^b   Gutierrez, Claudia ^c   Aymard, Guy ^a   Rouby, Jean Jacques ^a   Arbelot, Charlotte ^d   Brisson, Hélène ^d   Bouhemad, Belaïd ^d   Soummer, Alexis ^d   Ferrari, Fabio ^d   Monsel, Antoine ^d   Bodin, Liliane ^d   Luo, Rubin ^b   Zhang, Mao ^b   Aubry, Alexandra ^a   Brossier, Florence ^a   Robert, Jèrôme ^a   Jarlier, Vincent ^a   Lechat, Philippe ^a   Funck Brentan, Christian ^a   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

Aerosol; Amikacin; Ceftazidime; Pseudomonas aeruginosa; Ventilator associated pneumonia

Indexed keywords

AMIKACIN; CEFTAZIDIME; CIPROFLOXACIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BRONCHOSPASM; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FILTER; HEART ARREST; HUMAN; LUNG LAVAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; NEBULIZATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY AIRFLOW; RESUSCITATION; SUPERINFECTION; TOTAL LUNG CAPACITY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VENTILATOR ASSOCIATED PNEUMONIA;

ADMINISTRATION, INHALATION; AMIKACIN; ANTI-BACTERIAL AGENTS; CEFTAZIDIME; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80051573600     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201011-1894OC     Document Type: Article

References (36)

1. Rello J, Mariscal D, March F, Jubert P, Sanchez F, Valles J, Coll P. Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection? Am J Respir Crit Care Med 1998;157:912-916.
2. Crouch Brewer S, Wunderink RG, Jones CB, Leeper KV Jr., Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996;109:1019-1029. (Pubitemid 26113647)
3. Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, et al Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 2007;13:560-578. (Pubitemid 46730662)
4. Cavallo JD, Leblanc F, Fabre R. [Surveillance of Pseudomonas aeruginosa sensitivity to antibiotics in France and distribution of β-lactam resistance mechanisms: 1998 GERPB study] [article in French].Pathol Biol (Paris) 2000;48:472-477
5. Obritsch MD, Fish DN, MacLaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 2005;25:1353-1364. (Pubitemid 41407633)
6. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999;159:1127-1132. (Pubitemid 29230866)
7. Rouby JJ, Goldstein I, Lu Q. Inhaled antibiotic therapy. In: Tobin MJ, editor. Principles and practice of mechanical ventilation, 2nd ed. New York: McGraw-Hill Medical Publishing Division; 2006. Chapter 64, pp. 1311-1332.
8. Luyt CE, Clavel M, Guntupalli K, Johannigman J, Kennedy JI, Wood C, Corkery K, Gribben D, Chastre J. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care 2009;13:R200.
9. Goldstein I, Wallet F, Nicolas-Robin A, Ferrari F, Marquette CH, Rouby JJ. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am J Respir Crit Care Med 2002;166:1375-1381. (Pubitemid 35292705)
10. Ferrari F, Lu Q, Girardi C, Petitjean O, Marquette CH, Wallet F, Rouby JJ. Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa. Intensive Care Med 2009;35:1792-1800.
11. Lu Q, Ferarri F, Gutierrez C, Yang JX, Aymard G, Rouby JJ. Assessment of efficiency of nebulized ceftazidime and amikacin in patients with pneumonia caused by Pseudomonas aeruginosa [abstract]. Am J Respir Crit Care Med 2009;179:A5951.
12. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
13. Rouby JJ, Martin De Lassale E, Poete P, Nicolas MH, Bodin L, Jarlier V, Le Charpentier Y, Grosset J, Viars P. Nosocomial bronchopneumonia in the critically ill: histologic and bacteriologic aspects. Am Rev Respir Dis 1992;146:1059-1066.
14. Lu Q, Girardi C, Zhang M, Bouhemad B, Louchahi K, Petitjean O, Wallet F, Becquemin MH, Le Naour G, Marquette CH, et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med 2010;36:1147-1155.
15. Ferrari F, Liu ZH, Lu Q, Becquemin MH, Louchahi K, Aymard G, Marquette CH, Rouby JJ. Comparison of lung tissue concentrations of nebulized ceftazidime in ventilated piglets: ultrasonic versus vibrating plate nebulizers. Intensive Care Med 2008;34:1718-1723.
16. Lu Q, Malbouisson LM, Mourgeon E, Goldstein I, Coriat P, Rouby JJ. Assessment of PEEP-induced reopening of collapsed lung regions in acute lung injury: are one or three CT sections representative of the entire lung? Intensive Care Med 2001;27:1504-1510. (Pubitemid 32835319)
17. Puybasset L, Cluzel P, Gusman P, Grenier P, Preteux F, Rouby JJ; CT Scan ARDS Study Group. Regional distribution of gas and tissue in acute respiratory distress syndrome. I. Consequences for lung morphology. Intensive Care Med 2000;26:857-869. (Pubitemid 30616038)
18. Bouhemad B, Liu ZH, Arbelot C, Zhang M, Ferarri F, Le-Guen M, Girard M, Lu Q, Rouby JJ. Ultrasound assessment of antibiotic-induced pulmonary reaeration in ventilator-associated pneumonia. Crit Care Med 2010;38:84-92.
19. Girardi C, Tonnellier M, Goldstein I, Sartorius A, Wallet F, Rouby JJ. Lung deposition of continuous and intermittent intravenous ceftazidime in experimental Pseudomonas aeruginosa bronchopneumonia. Intensive Care Med 2006;32:2042-2048. (Pubitemid 44833119)
20. Lopez-Dupla M, Martinez JA, Vidal F, Almela M, Soriano A, Marco F, Lopez J, Olona M, Mensa J. Previous ciprofloxacin exposure is associated with resistance to b-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates. Am J Infect Control 2009;37:753-758.
21. Yang K, Zhuo H, Guglielmo BJ, Wiener-Kronish J. Multidrug-resistant Pseudomonas aeruginosa ventilator-associated pneumonia: the role of endotracheal aspirate surveillance cultures. Ann Pharmacother 2009;43:28-35.
22. Palmer LB, Smaldone GC, Chen JJ, Baram D, Duan T, Monteforte M, Varela M, Tempone AK, O'Riordan T, Daroowalla F, et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med 2008;36:2008-2013.
23. Dong Y, Zhao X, Domagala J, Drlica K. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 1999;43:1756-1758. (Pubitemid 29331261)
24. Dong Y, Zhao X, Kreiswirth BN, Drlica K. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000;44:2581-2584. (Pubitemid 30650925)
25. Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. Pharmacodynamics of cefepime in patients with gram-negative infections. J Antimicrob Chemother 2002;50:425-428.
26. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003;290:2588-2598. (Pubitemid 37443289)
27. Goldstein I, Chastre J, Rouby JJ. Novel and innovative strategies to treat ventilator-associated pneumonia: optimizing the duration of therapy and nebulizing antimicrobial agents. Semin Respir Crit Care Med 2006;27:82-91. (Pubitemid 43334732)
28. El Solh AA, Alhajhusain A. Update on the treatment of Pseudomonas aeruginosa pneumonia. J Antimicrob Chemother 2009;64:229-238.
29. El Solh AA, Akinnusi ME, Wiener-Kronish JP, Lynch SV, Pineda LA, Szarpa K. Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am J Respir Crit Care Med 2008;178:513-519.
30. Lacherade JC, De Jonghe B, Guezennec P, Debbat K, Hayon J, Monsel A, Fangio P, Appere de Vecchi C, Ramaut C, Outin H, et al. Intermittent subglottic secretion drainage and ventilator-associated pneumonia: a multicenter trial. Am J Respir Crit Care Med 2010;182:910-917.
31. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999;284:1318-1322. (Pubitemid 29289651)
32. Pneumatikos IA, Dragoumanis CK, Bouros DE. Ventilator-associated pneumonia or endotracheal tube-associated pneumonia? An approach to the pathogenesis and preventive strategies emphasizing the importance of endotracheal tube. Anesthesiology 2009;110:673-680.
33. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-1596. (Pubitemid 43810035)
34. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003;31:2742-2751. (Pubitemid 38010630)
35. MacArthur RD, Miller M, Albertson T, Panacek E, Johnson D, Teoh L, Barchuk W. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis 2004;38:284-288. (Pubitemid 38113039)
36. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: eleventh informational supplement, Wayne, PA: NCCLS; 2001. pp. M100-S111.